PTCT Dividend: PTC Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

PTCT Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	1,779	806	937	698	538	380
Revenue Growth (YoY)	98%	-14%	34%	30%	42%	24%
Cost of Revenue	56	57	65	44	32	18
Gross Profit	1,722	749	872	654	506	361
Selling, General & Admin	334	300	332	326	285	245
Research & Development	446	534	666	651	540	477
Operating Expenses	789	891	1,094	1,068	880	783
Other Non Operating Income (Expenses)	20	8	6	-30	-43	85
Pretax Income	741	-363	-696	-587	-518	-402
Income Tax Expense	-10	0	-69	-28	5	35
Net Income	751	-363	-626	-559	-523	-438
Net Income Growth	-266%	-42%	12%	7%	19%	75%
Shares Outstanding (Diluted)	87.11	76.84	74.83	71.7	70.5	66
Shares Change (YoY)	13%	3%	4%	2%	7%	12%
EPS (Diluted)	8.62	-4.72	-8.37	-7.79	-7.43	-6.64
EPS Growth	-246%	-44%	7%	5%	12%	56%
Free Cash Flow	705	-114	-186	-388	-279	-211
Free Cash Flow Per Share	8.09	-1.48	-2.48	-5.41	-3.95	-3.19
Gross Margin	96.79%	92.92%	93.06%	93.69%	94.05%	95%
Operating Margin	52.44%	-17.61%	-23.58%	-59.31%	-69.51%	-110.78%
Profit Margin	42.21%	-45.03%	-66.8%	-80.08%	-97.21%	-115.26%
Free Cash Flow Margin	39.62%	-14.14%	-19.85%	-55.58%	-51.85%	-55.52%
EBITDA	965	-67	15	-286	-310	-378
EBITDA Margin	54.24%	-8.31%	1.6%	-40.97%	-57.62%	-99.47%
D&A For EBITDA	32	75	236	128	64	43
EBIT	933	-142	-221	-414	-374	-421
EBIT Margin	52.44%	-17.61%	-23.58%	-59.31%	-69.51%	-110.78%
Effective Tax Rate	-1.34%	0%	9.91%	4.77%	-0.96%	-8.7%